Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaucoma Devices: Progress On Multiple Fronts

Executive Summary

Recent progress on the US regulatory front is generating renewed interest in device-based glaucoma therapies, which potentially could grow to a multibillion-dollar industry. The list of companies targeting this space continues to expand, as does the variety of potential device-based solutions: the current pipeline includes several innovative and less invasive products and technologies designed to improve surgical outcomes, a growing number of advanced drug-delivery inserts to address the patient noncompliance issue that is so common in this arena, and some unique patient monitoring devices.

You may also be interested in...



Nicox PursuesTransformation Into Ophthalmic Specialty Company – And Partner

Nicox of France pins hopes on glaucoma drug Vesneo – targeted for FDA submission in second quarter 2015 – and recent purchase of Aciex Therapeutics to build itself into an international ophthalmic player and ‘partner of choice’ in Europe.

Glaucoma: Devices Go Eye-to-Eye With Drugs

This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.

Device Companies Set Their Sights on Glaucoma

Drug therapy has dominated glaucoma management for decades, but novel device technologies are shifting the way this disease is managed, adding promising new options to the previously limited treatment continuum. For companies active in this field, along with an increasing number of VCs targeting ophthalmology, this shift marks the beginning of a tremendous new opportunity--one that will involve challenges and risks, but that also offers a huge payoff for those able to provide the right technology at the right time.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel